Today, Boston Scientific announced positive 12-month data demonstrating that patients who were treated with the VICI VENOUS STENT System for iliac and femoral vein obstructions exhibited a high rate of patent, or open, target lesions. Primary safety and efficacy results from the VIRTUS trial...
Abbott announced positive results from a new multicenter study of the company's BurstDR stimulation which showed that lower-energy, intermittent doses of BurstDR stimulation — known as "microdosing" ...
Abbott ($ABT) today announced FDA approval of the TactiCath Contact Force Ablation Catheter, Sensor Enabled, a new ablation catheter designed to help physicians accurately and effectively treat atrial fibrillation (AFib). ...
Today the FDA issued a Letter to Health Care Providers about a recent publication in the Journal of the American Heart Association that suggests a possible increased risk of death at two years and beyond in patients with a type of peripheral arterial disease (PAD)...
Atrial Fibrillation (AFib) is the most common sustained arrhythmia, which increases stroke risk five-fold, and accounts for almost one-third of all strokes. In the U.S. alone, AFib is responsible for approximately 130,000 deaths and 750,000 hospitalizations every year....
Abbott ($ABT) announced today that it has exercised its option to purchase Cephea Valve Technologies, Inc., a privately held medical device company developing a less-invasive heart valve replacement technology...
Medtronic just launched one of the cooler medical device applications in an effort to help patients' pacemakers and mobile devices communicate with one another....
From CNET Magazine: Medical advances can keep the tiniest hearts beating.https://t.co/jPDCujs7Jx
— CNET News (@CNETNews) January 15, 2019
Olympus recently announced a plan to develop the company into a truly global medical technology company. The transformation plan is called, “Transform Olympus”, and will start April 1, 2019....
Shares of Medtronic fell 6.5% after Medtronic CEO, Omar Ishrak, said during a presentation at the J.P. Morgan Healthcare Conference that sales would fall at the mid-point of the company's yearly projections due to softness in their cardiac and vascular divisions....